Literature DB >> 11755164

Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats.

Akira Takahara1, Hajime Koganei, Tomoko Takeda, Seinosuke Iwata.   

Abstract

The in vivo antisympathetic property of a dual L/N-type Ca(2+) channel blocker cilnidipine compared with that of typical N-type Ca(2+) channel blockers has never been clarified. We investigated the effects of the drug on a sympathetic nerve-mediated vascular response and vasodilating action in rats in comparison with those of an N-type Ca(2+) channel blocker omega-conotoxin MVIIA. In pithed rats, omega-conotoxin MVIIA preferentially suppressed the sympathetic nerve stimulation-induced pressor response, whereas cilnidipine suppressed the pressor response induced by sympathetic nerve stimulation and angiotensin II. In anesthetized rats, cilnidipine or omega-conotoxin MVIIA decreased mean blood pressure, while heart rate was decreased by omega-conotoxin MVIIA, but slightly increased by cilnidipine. These results suggest that cilnidipine can affect sympathetic N-type Ca(2+) channels in addition to vascular L-type Ca(2+) channels in antihypertensive doses in the rat in vivo. The antisympathetic activity of cilnidipine is not excessive for an antihypertensive drug in comparison with that of omega-conotoxin MVIIA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11755164     DOI: 10.1016/s0014-2999(01)01521-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.

Authors:  Shizuka Aritomi; Hajime Koganei; Hirotaka Wagatsuma; Akira Mitsui; Tetsuya Ogawa; Kosaku Nitta; Tomoyuki Konda
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

Review 2.  The fourth-generation Calcium channel blocker: cilnidipine.

Authors:  K Sarat Chandra; G Ramesh
Journal:  Indian Heart J       Date:  2013-12

3.  An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation.

Authors:  Kazuko Tajiri; Jean-Baptiste Guichard; Xiaoyan Qi; Feng Xiong; Patrice Naud; Jean-Claude Tardif; Antoine Da Costa; Kazutaka Aonuma; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

4.  Comparison of anti-anginal effect of cilnidipine with those of nicardipine and nifedipine in the vasopressin-induced angina model of rats.

Authors:  Xin Cao; Yuji Nakamura; Takeshi Wada; Hiroko Izumi-Nakaseko; Kentaro Ando; Bingmei Zhu; Bin Xu; Akira Takahara; Masaki Saitoh; Atsushi Sugiyama
Journal:  Heart Vessels       Date:  2016-05-18       Impact factor: 2.037

5.  Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey.

Authors:  Kazuomi Kario; Saori Matsuda; Shinobu Nagahama; Yoshiki Kurose; Hitoshi Sugii; Tsukasa Teshima; Noriyuki Suzuki
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-03       Impact factor: 3.738

6.  L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.

Authors:  Tomohiko Kanaoka; Kouichi Tamura; Hiromichi Wakui; Masato Ohsawa; Kengo Azushima; Kazushi Uneda; Ryu Kobayashi; Tetsuya Fujikawa; Yuko Tsurumi-Ikeya; Akinobu Maeda; Mai Yanagi; Yoshiyuki Toya; Satoshi Umemura
Journal:  Int J Mol Sci       Date:  2013-08-16       Impact factor: 5.923

7.  The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.

Authors:  Kazuomi Kario; Shin-ichi Ando; Hidenori Kido; Jin Nariyama; Shin Takiuchi; Tetsuo Yagi; Toshiki Shimizu; Kazuo Eguchi; Minoru Ohno; Osamu Kinoshita; Takahisa Yamada
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-12-10       Impact factor: 3.738

8.  A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities.

Authors:  Rugmani Padmanabhan Iyer; Merry L Lindsey; Robert J Chilton
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-29       Impact factor: 3.738

9.  Effect of a novel calcium channel blocker on abnormal nocturnal blood pressure in hypertensive patients.

Authors:  Kazuomi Kario; Jin Nariyama; Hidenori Kido; Shin-ichi Ando; Shin Takiuchi; Kazuo Eguchi; Yawara Niijima; Toshiaki Ando; Makoto Noda
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-29       Impact factor: 3.738

10.  Ziconotide: a review of its pharmacology and use in the treatment of pain.

Authors:  Joseph G McGivern
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.